in this issue
Pharma/fine chemicals roundup—15 October 2013
4:35 AM MDT | October 15, 2013 | By DEEPTI RAMESH
Pharmaceutical ingredients: Demand rises as industry evolves with new regulations in EU, US
Pharmaceutical ingredients makers are seeing a rise in demand particularly due to the growing emerging markets, experts say. Regulatory changes in the European Union and the United States, however, are changing the operating landscape significantly. There are also continued consolidations, and the competitiveness of Chinese and Indian manufacturers is waning, experts say. Producers around the world, however, remain optimistic and expect the emerging markets to play a key role in the future.
SAFC invests in ADCs, expands HPAPI capacity
SAFC Commercial, the custom manufacturing and services business unit of Sigma-Aldrich, says it is expanding two of its manufacturing facilities in the United States to support drug manufacturers in bringing new targeted and cytotoxic therapies to market. SAFC is investing in commercial-scale manufacturing capacity for antibody drug conjugates (ADCs) at St. Louis, and expanding its high-potency active pharmaceutical ingredient (HPAPI) manufacturing and storage capacity at the Verona facility, near Madison, WI. The ADC expansion at the St. Louis site is expected to be completed by mid-2015.
ICIG acquires fine chemicals firm Allessa
International Chemical Investors Group (ICIG), a privately owned industrial holding company, says it has agreed to acquire Allessa (Frankfurt, Germany), from Casella GmbH. Allessa is a manufacturer of fine chemicals including pharmaceutical intermediates, and specialty chemicals. Financial terms were not disclosed. AllessaChemie and AllessaSyntec merged in December 2012, to form Allessa. Allessa has three production sites in Frankfurt and the company employs over 890 people.
Roche to invest $209 million to build ADC facility
Roche (Basel, Switzerland) says it will invest 190 million Swiss francs ($209 million) in the construction of a new production facility at Basel, which will support the manufacturing of antibody-drug conjugate (ADC) medicines. ADCs offer a new treatment method for cancer in which cancer cells are destroyed in a more targeted way, and healthy cells are less affected. The investment at Basel is expected to create 50 jobs. The construction of the new production facility will begin in January 2014; production at the unit will start by August 2016.
Evonik and Colorcon sign cooperation deal
Evonik Industries and Colorcon (Harleysville, PA) have signed a cooperation agreement for the market promotion and technical support of Acryl-EZE, aqueous acrylic enteric system. Prior to this agreement, the product was produced, distributed, marketed and supported solely by Colorcon to the pharmaceutical industry. The Acryl-EZE system, for the application of an enteric film coating for oral solid dosage forms, was originally co-developed by the two companies. It combines Evonik's enteric polymer, Eudragit L 100-55, with a fully or partially formulated coating system from Colorcon. “This new cooperation will expand our offering and bring more choices to our customers ranging from single functional excipients to fully formulated delayed release coating systems,” says Jean-Luc Herbeaux, head of the health care business line at Evonik. From now on, customers with enteric coating projects will have access to nine technology centers of Evonik and 20 technical services laboratories of Colorcon globally. The combined service offerings of Colorcon and Evonik include on site scale-up and production assistance, regulatory support, formulation and development support and technical training.
Teva to restructure operations, cut 5,000 jobs worldwide
Teva Pharmaceutical Industries (Petach Tikva, Israel), the world’s leading generic drugs maker, has announced plans to restructure its business, including a reduction of some 5,000 jobs, approximately 10% of its global workforce. The company says that these steps are part of its worldwide restructuring program, which includes divestment of noncore assets, improvement in manufacturing efficiency and reduction of excess capacity. The company expects to realize annualized cost savings of $2 billion by end 2017, compared with the previously guided $1.5 to $2 billion.
Tosoh joins Manufacturing Technology Association of Biologics
Tosoh says it has recently joined Japan’s Manufacturing Technology Association of Biologics, an association established and licensed by the Ministry of Economy, Trade and Industry (Tokyo) to promote individualized medicine through the development of fundamental technologies for biotechnology medicines. As a member, Tosoh aims to play a crucial role in developing antibody medicine manufacturing technologies and to contribute to making Japan’s biotechnology-based medical technologies competitive globally.